GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acticor Biotech SA (XPAR:ALACT) » Definitions » Institutional Ownership

Acticor Biotech (XPAR:ALACT) Institutional Ownership : 0.08% (As of May. 26, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Acticor Biotech Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Acticor Biotech's institutional ownership is 0.08%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Acticor Biotech's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Acticor Biotech's Float Percentage Of Total Shares Outstanding is 0.00%.


Acticor Biotech Institutional Ownership Historical Data

The historical data trend for Acticor Biotech's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acticor Biotech Institutional Ownership Chart

Acticor Biotech Historical Data

The historical data trend for Acticor Biotech can be seen below:

2023-06-30 2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31
Institutional Ownership 0.11 0.11 0.11 0.11 0.09 0.09 0.08 0.08 0.08 0.08

Acticor Biotech Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Acticor Biotech (XPAR:ALACT) Business Description

Traded in Other Exchanges
Address
82 Avenue du Maine, Wojo Building, Paris, FRA, 75014
Acticor Biotech SA is a clinical stage biopharmaceutical company. It is developing a treatment for cardiovascular emergencies, with a primary focus on Acute Ischemic Stroke.

Acticor Biotech (XPAR:ALACT) Headlines

No Headlines